Morgan Stanley Upgrades Solventum (SOLV) on Growth Potential

Solventum Corporation (NYSE:SOLV) ranks among the best medical stocks to buy according to analysts. On July 15, Morgan Stanley upgraded Solventum Corporation (NYSE:SOLV) from Equalweight to Overweight, assigning a price target of $103 for the company’s shares. The upgrade came as Morgan Stanley believes that Solventum Corporation (NYSE:SOLV) can “drive material value over the coming years” after the company’s debt reduction and sale of its P&F segment.

According to the firm, Solventum Corporation (NYSE:SOLV) can improve organic growth to about 4% and solve cost inefficiencies. In a bull market, this may result in earnings per share of almost $9 by 2028. Additionally, Morgan Stanley notes that investors are now presented with an opportunity, considering Solventum’s management has taken over the company much quicker than expected.

Solventum Corporation (NYSE:SOLV) is a healthcare company that was spun off from the 3M healthcare division. It develops, manufactures, and markets a range of solutions to meet the needs of patients and customers across the globe.

While we acknowledge the potential of SOLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.